CD8A and neoplasm: Concerning DSS, significantly better survival was predictably found in patients with no recurrences (adjusted P = 0.001), lower tumor grade (adjusted P = 0.046), absence of lymph nodes metastases (adjusted P = 0.041), and lower CD8+/Tregs ratio (adjusted P = 0.012), with an advantage at the borderline of significance in patients with smaller tumors (T1 + T2) (adjusted P = 0.058).